Meridian Bioscience, Unit 16, The Edge Business Centre, London, UK.
Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.
Methods Mol Biol. 2022;2511:53-65. doi: 10.1007/978-1-0716-2395-4_4.
COVID-19 disease caused by the novel SARS-CoV-2 virus represents a new challenge for healthcare systems. The molecular confirmation of infection is crucial to guide public health decision-making. This task could be made more difficult during the next influenza season. Thus, a rapid and user-friendly diagnostic test to discriminate SARS-CoV-2 from influenza viruses is urgently needed. Here, we present a multiplex quantitative polymerase chain reaction (qPCR) assay capable of distinguishing SARS-CoV-2 from influenza A and B cases. This assay benefits from the use of an inhibitor tolerant PCR mix which obviates the need for the rate-limiting extraction step, allowing for a more rapid and accurate analysis.
由新型 SARS-CoV-2 病毒引起的 COVID-19 疾病对医疗保健系统构成了新的挑战。感染的分子确认对于指导公共卫生决策至关重要。在下一个流感季节，这项任务可能会更加困难。因此，迫切需要一种快速且易于使用的诊断测试来区分 SARS-CoV-2 和流感病毒。在这里，我们提出了一种多重定量聚合酶链反应（qPCR）检测方法，能够区分 SARS-CoV-2 与流感 A 和 B 病例。该检测方法得益于使用了一种抑制物耐受的 PCR 混合物，从而省去了限速的提取步骤，使分析更加快速和准确。
